Any day now a conservative federal judge in Texas could upend the national abortion debate by requiring the FDA to rescind its approval of mifepristone, a drug approved in the U.S. more than 20 years ago that is now used in more than half of abortions nationwide. Meanwhile, a controversial study on masks gets a clarification, although it may be too late to change the public impression of what it found.

Alice Miranda Ollstein of Politico, Jessie Hellmann of CQ Roll Call, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more.

Click here for a transcript of the episode.

Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.

Julie Rovner: “Tradeoffs” podcast’s “The Conservative Clash Over Abortion Bans,” by Alice Miranda Ollstein and Dan Gorenstein

Alice Miranda Ollstein: Politico’s “Sharpton Dodges the Spotlight on Latest Push to Ban Menthol Cigarettes,” by Julia Marsh

Sarah Karlin-Smith: Allure’s “With New Legislation, You Can Expect More Recalls to Hit the Beauty Industry,” by Elizabeth Siegel and Deanna Pai

Jessie Hellmann: The New York Times’ “Opioid Settlement Hinders Patients’ Access to a Wide Array of Drugs,” by Christina Jewett and Ellen Gabler

Hosted on Acast. See acast.com/privacy for more information.